Synthetic	O
lethal	O
genetic	O
interactions	O
between	O
Rad54	B-GP
and	O
PARP	B-GP
-	I-GP
1	I-GP
in	O
mouse	B-OG
development	O
and	O
oncogenesis	O

Mutations	O
in	O
DNA	O
repair	O
pathways	O
are	O
frequent	O
in	O
human	B-OG
cancers	B-DS
.	O

Hence	O
,	O
gaining	O
insights	O
into	O
the	O
interaction	O
of	O
DNA	O
repair	O
genes	O
is	O
key	O
to	O
development	O
of	O
novel	O
tumor	B-DS
-	O
specific	O
treatment	O
strategies	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
functional	O
relationship	O
in	O
development	O
and	O
oncogenesis	O
between	O
the	O
homologous	O
recombination	O
(	O
HR	O
)	O
factor	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
,	O
a	O
nuclear	O
enzyme	O
that	O
plays	O
a	O
multifunctional	O
role	O
in	O
DNA	O
damage	O
signaling	O
and	O
repair	O
.	O

We	O
introduced	O
single	O
or	O
combined	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inactivating	O
germline	O
mutations	O
in	O
Ptc1	B-GP
heterozygous	O
mice	B-OG
,	O
a	O
well	O
-	O
characterized	O
model	O
of	O
medulloblastoma	B-DS
,	O
the	O
most	O
common	O
malignant	O
pediatric	B-DS
brain	I-DS
tumor	I-DS
.	O

Our	O
study	O
reveals	O
that	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
causes	O
a	O
marked	O
growth	O
delay	O
culminating	O
in	O
perinatallethality	O
,	O
providing	O
for	O
the	O
first	O
time	O
evidence	O
of	O
synthetic	O
lethal	O
interactions	O
between	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
vivo	O
.	O

Although	O
the	O
double	O
mutation	O
hampered	O
investigation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
interactions	O
in	O
cerebellum	O
tumorigenesis	O
,	O
insights	O
were	O
gained	O
by	O
showing	O
accumulation	O
of	O
endogenous	O
DNA	O
damage	O
and	O
increased	O
apoptotic	O
rate	O
in	O
granule	O
cell	O
precursors	O
(	O
GCPs	O
).	O

A	O
network	O
-	O
based	O
approach	O
to	O
detect	O
differential	O
expression	O
of	O
DNA	O
repair	O
genes	O
in	O
the	O
cerebellum	O
revealed	O
perturbation	O
of	O
p53	B-GP
signaling	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-,	O
and	O
MEFs	O
from	O
combined	O
Rad54	B-GP
/	O
Parp	B-GP
-	I-GP
1	I-GP
mutants	O
showed	O
p53	B-GP
/	O
p21	B-GP
-	O
dependent	O
typical	O
senescent	O
features	O
.	O

These	O
findings	O
help	O
elucidate	O
the	O
genetic	O
interplay	O
between	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
by	O
suggesting	O
that	O
p53	B-GP
/	O
p21	B-GP
-	O
mediated	O
apoptosis	O
and	O
/	O
or	O
senescence	O
may	O
be	O
involved	O
in	O
synthetic	O
lethal	O
interactions	O
occurring	O
during	O
development	O
and	O
inhibition	O
of	O
tumor	B-DS
growth	O
.	O

INTRODUCTION	O

The	O
complex	O
network	O
of	O
DNA	O
repair	O
system	O
in	O
mammals	B-OG
counteracts	O
genome	O
insult	O
and	O
maintains	O
genomic	O
stability	O
.	O

DNA	O
repair	O
failure	O
increases	O
mutations	O
frequency	O
and	O
affects	O
cell	O
-	O
cycle	O
regulation	O
,	O
promoting	O
tumorigenesis	O
;	O
in	O
fact	O
,	O
inactivating	O
mutations	O
in	O
DNA	O
repair	O
pathways	O
are	O
frequent	O
in	O
cancer	B-DS
.	O

On	O
the	O
other	O
hand	O
,	O
DNA	O
repair	O
defects	O
provide	O
new	O
therapeutic	O
opportunities	O
to	O
treat	O
cancer	B-DS
through	O
DNA	O
-	O
damage	O
-	O
inducing	O
radiation	O
and	O
chemotherapies	O
.	O

Identification	O
of	O
synthetic	O
interactions	O
,	O
i	O
.	O
e	O
.,	O
negative	O
genetic	O
combination	O
of	O
mutations	O
in	O
two	O
or	O
more	O
genes	O
,	O
leading	O
to	O
severe	O
slow	O
growth	O
or	O
lethality	O
compared	O
to	O
single	O
mutants	O
,	O
has	O
grown	O
in	O
popularity	O
in	O
the	O
DNA	O
damage	O
field	O
,	O
with	O
the	O
finding	O
that	O
poly	B-GP
(	I-GP
ADP	I-GP
-	I-GP
ribose	I-GP
)	I-GP
polymerase	I-GP
(	O
Parp	B-GP
-	I-GP
1	I-GP
)	O
inhibitors	O
show	O
synthetically	O
lethal	O
effects	O
in	O
homologous	O
recombination	O
(	O
HR	O
)	O
defective	O
tumors	B-DS
[	O
1	O
].	O

PolyADP	O
-	O
ribosylation	O
acts	O
in	O
DNA	O
-	O
damage	O
repair	O
response	O
and	O
maintenance	O
mechanisms	O
of	O
genomic	O
stability	O
.	O

Several	O
DNA	O
repair	O
pathways	O
,	O
including	O
base	O
-	O
excision	O
repair	O
and	O
double	O
strand	O
break	O
(	O
DSB	O
)	O
repair	O
,	O
involve	O
Parp	B-GP
functions	O
.	O

Inhibition	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
results	O
in	O
an	O
increase	O
in	O
single	O
strand	O
breaks	O
(	O
SSBs	O
)	O
that	O
then	O
collapse	O
replication	O
forks	O
into	O
toxic	O
one	O
-	O
ended	O
DSBs	O
[	O
1	O
,	O
2	O
],	O
which	O
are	O
substrates	O
for	O
HR	O
[	O
3	O
,	O
4	O
].	O

In	O
addition	O
,	O
through	O
enzyme	O
-	O
dependent	O
chromatin	O
remodeling	O
and	O
enzyme	O
-	O
independent	O
motif	O
recognition	O
,	O
Parp	B-GP
-	I-GP
1	I-GP
also	O
plays	O
important	O
roles	O
in	O
regulating	O
gene	O
expression	O
[	O
5	O
].	O

Furthermore	O
,	O
Parp	B-GP
-	I-GP
1	I-GP
binding	O
motifs	O
may	O
be	O
readily	O
found	O
in	O
promoter	O
elements	O
of	O
DNA	O
repair	O
genes	O
,	O
linking	O
DNA	O
repair	O
and	O
transcription	O
functions	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
[	O
5	O
].	O

The	O
critical	O
role	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
maintenance	O
of	O
genomic	O
stability	O
is	O
reflected	O
in	O
its	O
frequent	O
upregulation	O
in	O
cancer	B-DS
[	O
6	O
,	O
7	O
],	O
and	O
by	O
hypersensitivity	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
null	O
animals	B-OG
toward	O
the	O
mutagenic	O
effect	O
of	O
DNA	O
damaging	O
agents	O
[	O
8	O
].	O

The	O
Rad54	B-GP
gene	O
encodes	O
a	O
dsDNA	O
-	O
dependent	O
ATPase	B-GP
of	O
the	O
Swi2	B-GP
/	O
Snf2	B-GP
family	O
[	O
9	O
],	O
which	O
interacts	O
directly	O
with	O
Rad51	B-GP
[	O
10	O
,	O
11	O
],	O
and	O
stimulates	O
its	O
DNA	O
exchange	O
activity	O
[	O
12	O
].	O

Rad54	B-GP
promotes	O
chromatin	O
remodeling	O
,	O
Rad51	B-GP
displacement	O
from	O
double	O
-	O
stranded	O
DNA	O
,	O
binds	O
Holliday	O
junctions	O
and	O
drives	O
their	O
branch	O
migration	O
[	O
13	O
].	O

Although	O
disruption	O
of	O
other	O
genes	O
involved	O
in	O
HR	O
leads	O
to	O
embryonic	O
lethality	O
,	O
adult	O
Rad54	B-GP
-/-	O
mice	B-OG
are	O
viable	O
and	O
fertile	O
,	O
providing	O
a	O
valuable	O
model	O
to	O
study	O
the	O
effects	O
of	O
attenuated	O
HR	O
.	O

Interestingly	O
,	O
several	O
point	O
mutations	O
in	O
conserved	O
regions	O
of	O
the	O
Rad54	B-GP
gene	O
family	O
have	O
been	O
found	O
in	O
primary	B-DS
tumors	I-DS
(	O
e	O
.	O
g	O
.,	O
breast	O
and	O
colon	B-DS
carcinomas	I-DS
and	O
lymphomas	B-DS
)	O
[	O
14	O
,	O
15	O
],	O
and	O
approximately	O
half	O
of	O
epithelial	B-DS
ovarian	I-DS
cancers	I-DS
have	O
alterations	O
in	O
genes	O
regulating	O
HR	O
repair	O
[	O
16	O
].	O

Most	O
DNA	O
repair	O
pathways	O
are	O
complex	O
,	O
involving	O
many	O
proteins	O
working	O
in	O
discrete	O
consecutive	O
steps	O
.	O

Therefore	O
,	O
their	O
balanced	O
and	O
coordinated	O
expression	O
is	O
important	O
to	O
avoid	O
erroneous	O
repair	O
that	O
might	O
result	O
from	O
excessive	O
base	O
removal	O
and	O
DNA	O
cleavage	O
.	O

In	O
addition	O
,	O
as	O
DNA	O
damage	O
is	O
a	O
likely	O
factor	O
in	O
promoting	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
pathophysiology	O
,	O
DNA	O
repair	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
maintenance	O
of	O
normal	O
physiological	O
function	O
.	O

In	O
this	O
study	O
,	O
to	O
investigate	O
the	O
functional	O
relationship	O
between	O
the	O
HR	O
factor	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
development	O
and	O
oncogenesis	O
in	O
vivo	O
,	O
we	O
introduced	O
single	O
or	O
combined	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inactivating	O
mutations	O
in	O
a	O
well	O
characterized	O
cancer	B-DS
model	O
,	O
the	O
Ptc1	B-GP
heterozygous	O
mice	B-OG
.	O

Mice	B-OG
in	O
which	O
one	O
copy	O
the	O
Ptc1	B-GP
gene	O
has	O
been	O
inactivated	O
(	O
Ptc1	B-GP
+/-)	O
are	O
developmentally	O
nearly	O
normal	O
,	O
but	O
show	O
a	O
marked	O
predisposition	O
to	O
tumor	B-DS
development	O
,	O
including	O
medulloblastoma	B-DS
(	O
MB	B-DS
),	O
a	O
frequent	O
pediatric	O
malignant	B-DS
tumor	I-DS
of	I-DS
the	I-DS
cerebellum	I-DS
[	O
17	O
,	O
18	O
].	O

Our	O
previous	O
work	O
showed	O
that	O
neonatal	O
irradiation	O
dramatically	O
increases	O
the	O
frequency	O
of	O
MB	B-DS
[	O
19	O
,	O
20	O
].	O

We	O
also	O
showed	O
that	O
combined	O
loss	O
of	O
Ptc1	B-GP
and	O
Rad54	B-GP
or	O
of	O
Ptc1	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
increased	O
radiation	O
induced	O
MB	B-DS
[	O
21	O
,	O
22	O
].	O

Here	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
combined	O
loss	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
the	O
Ptc1	B-GP
mouse	B-OG
model	O
of	O
spontaneous	O
and	O
radiation	B-DS
-	I-DS
induced	I-DS
cancer	I-DS
,	O
highlighting	O
novel	O
synthetic	O
lethal	O
interactions	O
during	O
development	O
and	O
tumorigenesis	O
,	O
and	O
dissecting	O
the	O
underlying	O
cellular	O
and	O
molecular	O
mechanisms	O
.	O

RESULTS	O

Survival	O
and	O
oncogenesis	O
in	O
crosses	O
between	O
Rad54	B-GP
,	O
Parp	B-GP
-	I-GP
1	I-GP
and	O
Ptc1	B-GP
mutant	O
mice	B-OG

Defects	O
in	O
DNA	O
damage	O
signaling	O
are	O
frequently	O
associated	O
with	O
neurodegeneration	O
,	O
neurodevelopmental	O
disease	O
and	O
brain	B-DS
tumors	I-DS
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
oncogenic	O
potential	O
of	O
combined	O
genetic	O
disruption	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
the	O
CNS	O
by	O
knocking	O
out	O
these	O
genes	O
in	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O

To	O
this	O
aim	O
,	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/+	O
mice	B-OG
were	O
intercrossed	O
,	O
and	O
the	O
progeny	O
genotyped	O
.	O

For	O
simplification	O
,	O
wt	O
genotypes	O
are	O
hereafter	O
omitted	O
from	O
the	O
label	O
,	O
unless	O
differently	O
specified	O
.	O

Mutants	O
for	O
Rad54	B-GP
(	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-)	O
or	O
Parp	B-GP
-	I-GP
1	I-GP
(	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-)	O
were	O
viable	O
.	O

Irrespective	O
of	O
Ptc1	B-GP
genotype	O
,	O
no	O
mice	B-OG
with	O
compound	O
Rad54	B-GP
/	O
Parp	B-GP
-	I-GP
1	I-GP
inactivation	O
were	O
found	O
at	O
weaning	O
,	O
showing	O
strong	O
synthetic	O
lethal	O
interaction	O
between	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
genes	O
in	O
vivo	O
,	O
in	O
agreement	O
with	O
existing	O
in	O
vitro	O
data	O
.	O

To	O
look	O
for	O
haploinsufficient	O
interactions	O
,	O
compound	O
mutant	O
mice	B-OG
with	O
varying	O
gene	O
dosage	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
were	O
analyzed	O
for	O
survival	O
and	O
cerebellum	O
tumorigenesis	O
,	O
with	O
or	O
without	O
irradiation	O
.	O

Because	O
only	O
Ptc1	B-GP
+/-	O
mice	B-OG
are	O
prone	O
to	O
MB	B-DS
,	O
the	O
effects	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inactivation	O
was	O
evaluated	O
only	O
in	O
mice	B-OG
with	O
Ptc1	B-GP
+/-	O
genotype	O
.	O

Lack	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
,	O
or	O
Rad54	B-GP
per	O
se	O
affected	O
lifespan	O
of	O
Ptc1	B-GP
+/-	O
mice	B-OG
by	O
significantly	O
shortening	O
the	O
median	O
survival	O
time	O
from	O
64	O
to	O
14	O
(	O
P	O
˂	O
0	O
.	O
0001	O
)	O
or	O
45	O
weeks	O
(	O
P	O
=	O
0	O
.	O
0206	O
),	O
respectively	O
(	O
Figure	O
1A	O
and	O
1C	O
).	O

However	O
,	O
loss	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
function	O
had	O
more	O
severe	O
effects	O
on	O
survival	O
compared	O
to	O
Rad54	B-GP
loss	O
(	O
i	O
.	O
e	O
.,	O
14	O
vs	O
45	O
weeks	O
;	O
P	O
=	O
0	O
.	O
0002	O
)	O
(	O
Figure	O
1A	O
),	O
suggesting	O
a	O
preferential	O
role	O
for	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
resolution	O
of	O
spontaneous	O
DNA	O
damage	O
compared	O
to	O
Rad54	B-GP
.	O

Irradiation	O
of	O
Ptc1	B-GP
+/-	O
mice	B-OG
or	O
Ptc1	B-GP
/	O
Rad54	B-GP
compound	O
mutants	O
(	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-)	O
with	O
1	O
Gy	O
of	O
x	O
-	O
rays	O
caused	O
a	O
sharp	O
reduction	O
of	O
lifespan	O
relative	O
to	O
controls	O
(	O
17	O
vs	O
64	O
weeks	O
P	O
˂	O
0	O
.	O
0001	O
;	O
13	O
vs	O
45	O
weeks	O
;	O
P	O
=	O
0	O
.	O
0002	O
;	O
Figure	O
1A	O
-	O
1C	O
),	O
with	O
median	O
survival	O
reduced	O
approximately	O
3	O
-	O
fold	O
.	O

Notably	O
,	O
life	O
shortening	O
was	O
not	O
affected	O
by	O
Rad54	B-GP
status	O
,	O
in	O
agreement	O
with	O
findings	O
that	O
Rad54	B-GP
-/-	O
mice	B-OG
are	O
not	O
hypersensitive	O
to	O
radiation	O
[	O
23	O
].	O

Moreover	O
,	O
irradiated	O
Ptc1	B-GP
/	O
Parp	B-GP
-	I-GP
1	I-GP
compound	O
mutants	O
(	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-)	O
did	O
not	O
show	O
further	O
survival	O
reduction	O
compared	O
to	O
controls	O
(	O
15	O
vs	O
14	O
weeks	O
;	O
P	O
=	O
0	O
.	O
862	O
;	O
Figure	O
1A	O
-	O
1C	O
).	O

The	O
lack	O
of	O
modifying	O
effects	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
on	O
Ptc1	B-GP
-	O
associated	O
radiosensitivity	O
is	O
consistent	O
with	O
previous	O
reports	O
from	O
our	O
laboratory	O
[	O
22	O
].	O

Effect	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inactivation	O
on	O
survival	O
and	O
tumor	B-DS
development	O

(	O
A	O
)	O
Survival	O
curves	O
of	O
unirradiated	O
Ptc1	B-GP
+/-	O
,	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
showing	O
significant	O
lifespan	O
shortening	O
after	O
inactivation	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
.	O
(	O
B	O
)	O
Survival	O
curves	O
of	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
irradiated	O
with	O
1Gy	O
at	O
P1	O
,	O
all	O
showing	O
significant	O
lifespan	O
shortening	O
compared	O
to	O
control	O
mice	B-OG
with	O
exception	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
null	O
mice	B-OG
(	O
Rad54	B-GP
+/+	O
or	O
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-).	O
(	O
C	O
)	O
Median	O
survival	O
of	O
unirradiated	O
and	O
irradiated	O
mice	B-OG
.	O
(	O
D	O
)	O
Effect	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inactivation	O
on	O
spontaneous	O
and	O
(	O
E	O
)	O
radiation	O
-	O
induced	O
medulloblastoma	B-DS
tumorigenesis	O
.	O
(	O
F	O
)	O
Percent	O
incidence	O
of	O
medulloblastoma	B-DS
,	O
sarcoma	B-DS
and	O
other	O
tumors	B-DS
for	O
each	O
mouse	B-OG
group	O
.	O
*	O
P	O
≤	O
0	O
.	O
05	O
;	O
**	O
P	O
≤	O
0	O
.	O
005	O
;	O
***	O
P	O
≤	O
0	O
.	O
0001	O
.	O

Coherent	O
with	O
survival	O
reduction	O
,	O
genetic	O
disruption	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
significantly	O
increased	O
spontaneous	O
MB	B-DS
incidence	O
in	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
50	O
%	O
vs	O
14	O
%	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0038	O
)	O
or	O
in	O
Ptc1	B-GP
+/-	O
mice	B-OG
lacking	O
Rad54	B-GP
(	O
i	O
.	O
e	O
.,	O
the	O
viable	O
genotypes	O
:	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
44	O
%	O
vs	O
15	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0274	O
)	O
(	O
Figure	O
1D	O
-	O
1F	O
).	O

Irradiation	O
of	O
Ptc1	B-GP
+/-	O
(	O
Ptc1	B-GP
+/-)	O
or	O
Rad54	B-GP
-/-	O
mice	B-OG
(	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-)	O
caused	O
significantly	O
increase	O
MB	B-DS
incidence	O
compared	O
with	O
unirradiated	O
mice	B-OG
,	O
both	O
in	O
wt	O
Parp	B-GP
-	I-GP
1	I-GP
background	O
[	O
Ptc1	B-GP
+/-	O
(	O
82	O
%	O
vs	O
14	O
%;	O
P	O
=	O
0	O
.	O
0001	O
);	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-	O
(	O
84	O
%	O
vs	O
15	O
%;	O
P	O
=	O
0	O
.	O
0001	O
)]	O
and	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
heterozygotes	O
(	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-	O
56	O
%	O
vs	O
30	O
%;	O
P	O
=	O
0	O
.	O
0447	O
)	O
(	O
Figure	O
1D	O
-	O
1F	O
).	O

In	O
contrast	O
,	O
irradiation	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
caused	O
a	O
non	O
-	O
statistical	O
increase	O
of	O
their	O
already	O
high	O
MB	B-DS
incidence	O
(	O
75	O
%	O
vs	O
50	O
%;	O
P	O
=	O
0	O
.	O
1717	O
).	O

This	O
difference	O
became	O
significant	O
only	O
in	O
mice	B-OG
with	O
concurrent	O
inactivation	O
of	O
one	O
copy	O
of	O
Rad54	B-GP
[(	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
)	O
(	O
79	O
%	O
vs	O
44	O
%;	O
P	O
=	O
0	O
.	O
0378	O
)]	O
(	O
Figure	O
1E	O
and	O
1F	O
).	O

Notably	O
,	O
in	O
a	O
null	O
Rad54	B-GP
background	O
deletion	O
of	O
one	O
Parp	B-GP
-	I-GP
1	I-GP
allele	O
caused	O
significantly	O
lower	O
radiation	O
-	O
induced	O
MB	B-DS
tumorigenesis	O
compared	O
with	O
Parp	B-GP
-	I-GP
1	I-GP
wt	O
mice	B-OG
[	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-	O
(	O
56	O
%)	O
vs	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
84	O
%),	O
P	O
=	O
0	O
.	O
0439	O
]	O
(	O
Figure	O
1E	O
and	O
1F	O
),	O
suggesting	O
a	O
lethal	O
haploinsufficient	O
interaction	O
between	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
the	O
context	O
of	O
radiation	O
oncogenesis	O
.	O

In	O
all	O
groups	O
,	O
irradiation	O
increased	O
the	O
incidence	O
of	O
MB	B-DS
,	O
an	O
early	O
-	O
onset	O
tumor	B-DS
.	O

This	O
was	O
reflected	O
in	O
decreased	O
incidence	O
of	O
late	O
occurring	O
tumors	B-DS
,	O
including	O
sarcomas	B-DS
and	O
other	O
tumors	B-DS
(	O
Figure	O
1F	O
),	O
with	O
exception	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
in	O
which	O
MB	B-DS
mortality	O
was	O
already	O
high	O
and	O
did	O
not	O
significantly	O
increase	O
with	O
irradiation	O
.	O

Loss	O
of	O
the	O
normal	O
Ptc1	B-GP
allele	O
is	O
the	O
causative	O
event	O
in	O
MB	B-DS
development	O
in	O
Ptc1	B-GP
+/-	O
mice	B-OG
[	O
24	O
].	O

To	O
test	O
if	O
single	O
or	O
combined	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
deficiency	O
alters	O
the	O
typical	O
chr	O
-	O
13	O
LOH	O
pattern	O
in	O
MB	B-DS
,	O
we	O
performed	O
microsatellite	O
analysis	O
with	O
a	O
set	O
of	O
markers	O
spanning	O
the	O
length	O
of	O
chr	O
-	O
13	O
,	O
where	O
Ptc1	B-GP
gene	O
is	O
located	O
(	O
Figure	O
S1	O
).	O

Within	O
the	O
sample	O
size	O
,	O
no	O
obvious	O
differences	O
were	O
observed	O
in	O
Ptc1	B-GP
LOH	O
pattern	O
in	O
single	O
or	O
compound	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
mutants	O
.	O

Combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
causes	O
growth	O
retardation	O
and	O
perinatal	O
lethality	O

The	O
complete	O
lack	O
of	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
null	O
mice	B-OG
in	O
our	O
triple	O
cross	O
at	O
weaning	O
age	O
prompted	O
us	O
to	O
investigate	O
the	O
effect	O
of	O
this	O
genetic	O
interaction	O
at	O
earlier	O
developmental	O
times	O
.	O

Analysis	O
of	O
the	O
genotype	O
distribution	O
in	O
the	O
offspring	O
at	O
postnatal	O
day	O
1	O
(	O
P1	O
)	O
revealed	O
that	O
,	O
of	O
764	O
newborns	O
derived	O
from	O
heterozygous	O
mating	O
,	O
only	O
10	O
and	O
13	O
in	O
wt	O
and	O
Ptc1	B-GP
+/-	O
genetic	O
backgrounds	O
,	O
respectively	O
,	O
were	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
compound	O
mutants	O
,	O
far	O
below	O
the	O
24	O
mice	B-OG
expected	O
based	O
on	O
a	O
Mendelian	O
inheritance	O
ratio	O
of	O
25	O
%,	O
although	O
this	O
trend	O
reached	O
statistical	O
significance	O
only	O
in	O
Ptc1	B-GP
+/+	O
mice	B-OG
(	O
Table	O
1	O
).	O

In	O
addition	O
,	O
double	O
knockout	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
pups	O
at	O
P1	O
and	O
P7	O
showed	O
significantly	O
smaller	O
body	O
size	O
compared	O
to	O
relative	O
littermates	O
(	O
Figure	O
2A	O
and	O
2C	O
).	O

In	O
fact	O
,	O
inactivation	O
of	O
both	O
genes	O
significantly	O
reduced	O
body	O
weight	O
at	O
P1	O
(	O
by	O
34	O
%	O
in	O
wt	O
and	O
17	O
%	O
in	O
Ptc1	B-GP
+/-	O
genotypes	O
)	O
and	O
P7	O
(	O
by	O
37	O
%	O
in	O
wt	O
and	O
20	O
%	O
in	O
Ptc1	B-GP
+/-	O
genotypes	O
),	O
showing	O
that	O
combined	O
loss	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
causes	O
severe	O
growth	O
retardation	O
(	O
Figure	O
2A	O
-	O
2D	O
).	O

Moreover	O
,	O
45	O
%	O
and	O
29	O
%	O
of	O
the	O
double	O
mutants	O
on	O
Ptc1	B-GP
+/-	O
and	O
wt	O
background	O
,	O
respectively	O
,	O
dyed	O
during	O
the	O
first	O
fortnight	O
of	O
life	O
and	O
none	O
survived	O
to	O
weaning	O
age	O
(	O
data	O
not	O
shown	O
).	O

Genotype	O
distribution	O
in	O
the	O
offspring	O
of	O
the	O
intercross	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/+	O
x	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-	O
at	O
birth	O

Genotype	O

Expected	O

Observed	O
(%)	O

Rad54	B-GP

Parp	B-GP
-	I-GP
1	I-GP

Ptc1	B-GP

Total	O
mice	B-OG
=	O
764	O

+/+	O

+/+	O

+/+	O

24	O

17	O
(	O
71	O
)	O

+/+	O

+/+	O

+/-	O

24	O

26	O
(	O
109	O
)	O

-/-	O

+/+	O

+/+	O

24	O

29	O
(	O
121	O
)	O

-/-	O

+/+	O

+/-	O

24	O

21	O
(	O
88	O
)	O

+/+	O

-/-	O

+/+	O

24	O

20	O
(	O
84	O
)	O

+/+	O

-/-	O

+/-	O

24	O

14	O
(	O
58	O
)	O

-/-	O

-/-	O

+/+	O

24	O

10	O
(	O
41	O
)	O
*	O

-/-	O

-/-	O

+/-	O

24	O

13	O
(	O
54	O
)	O
1	O

The	O
table	O
represents	O
expected	O
and	O
observed	O
genotype	O
distribution	O
in	O
the	O
offspring	O
at	O
birth	O
.	O

Compound	O
mutants	O
were	O
born	O
at	O
numbers	O
below	O
the	O
predicted	O
Mendelian	O
inheritance	O
ratio	O
.	O

Mice	B-OG
heterozygous	O
for	O
Rad54	B-GP
and	O
/	O
or	O
Parp	B-GP
-	I-GP
1	I-GP
are	O
not	O
shown	O
.	O
*	O
P	O
≤	O
0	O
,	O
05	O
;	O
1P	O
=	O
0	O
,	O
0948	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

Effect	O
of	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
on	O
mouse	B-OG
development	O

Left	O
in	O
(	O
A	O
)	O
and	O
(	O
C	O
)	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
mice	B-OG
exhibited	O
reduced	O
size	O
compared	O
to	O
wt	O
and	O
Ptc1	B-GP
+/-	O
littermates	O
(	O
right	O
)	O
at	O
(	O
A	O
)	O
postnatal	O
day	O
1	O
and	O
(	O
C	O
)	O
7	O
.	O

Double	O
knockout	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
mice	B-OG
showed	O
significantly	O
reduced	O
body	O
weight	O
at	O
(	O
B	O
)	O
postnatal	O
day	O
1	O
and	O
(	O
D	O
)	O
7	O
compared	O
wt	O
and	O
Ptc1	B-GP
+/-	O
littermates	O
,	O
demonstrating	O
that	O
combined	O
loss	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
causes	O
severe	O
growth	O
retardation	O
.	O

The	O
number	O
of	O
mice	B-OG
used	O
per	O
test	O
is	O
indicated	O
in	O
the	O
graph	O
(	O
n	O
).	O
*	O
P	O
≤	O
0	O
.	O
05	O
;	O
**	O
P	O
≤	O
0	O
.	O
005	O
;	O
***	O
P	O
≤	O
0	O
.	O
0001	O
.	O

Effects	O
of	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
on	O
cerebellum	O
morphogenesis	O

To	O
further	O
clarify	O
the	O
underlying	O
mechanisms	O
of	O
synthetic	O
lethal	O
interactions	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
perturbation	O
,	O
we	O
focused	O
on	O
the	O
cerebellum	O
,	O
from	O
which	O
MB	B-DS
originates	O
.	O

The	O
well	O
-	O
characterized	O
developmental	O
processes	O
and	O
stereotypical	O
foliation	O
pattern	O
make	O
this	O
organ	O
particularly	O
amenable	O
to	O
the	O
study	O
of	O
factors	O
affecting	O
development	O
,	O
leading	O
to	O
abnormal	O
morphology	O
or	O
function	O
.	O

By	O
measuring	O
the	O
cross	O
-	O
sectional	O
area	O
of	O
developing	O
cerebellum	O
at	O
P1	O
and	O
P7	O
we	O
show	O
that	O
,	O
in	O
line	O
with	O
generalized	O
growth	O
delay	O
,	O
significant	O
decrease	O
in	O
size	O
was	O
observed	O
in	O
cerebella	O
from	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
mutants	O
at	O
P1	O
and	O
P7	O
relative	O
to	O
Ptc1	B-GP
+/+	O
mice	B-OG
(	O
by	O
36	O
%	O
at	O
P1	O
,	O
P	O
=	O
0	O
.	O
0035	O
,	O
and	O
31	O
%	O
at	O
P7	O
,	O
P	O
=	O
0	O
.	O
0078	O
;	O
Figure	O
3	O
).	O

Similarly	O
decreased	O
cerebellum	O
area	O
was	O
observed	O
in	O
double	O
null	O
mice	B-OG
with	O
Ptc1	B-GP
+/-	O
genotype	O
(	O
by	O
34	O
%	O
at	O
P1	O
,	O
P	O
=	O
0	O
.	O
0007	O
and	O
43	O
%	O
at	O
P7	O
,	O
P	O
=	O
0	O
.	O
0012	O
)	O
(	O
Figure	O
3A	O
-	O
3F	O
).	O

In	O
keeping	O
with	O
growth	O
delay	O
,	O
cerebella	O
from	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
showed	O
shallow	O
principal	O
fissures	O
at	O
P1	O
relative	O
to	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
asterisks	O
in	O
Figure	O
3C	O
).	O

In	O
addition	O
,	O
delayed	O
lobularization	O
was	O
evident	O
at	O
P7	O
(	O
Figure	O
3E	O
and	O
3F	O
).	O

Effect	O
of	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
the	O
developing	O
cerebellum	O

Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
double	O
mutant	O
mice	B-OG
show	O
significant	O
reduction	O
of	O
cerebellum	O
area	O
compared	O
to	O
wt	O
and	O
Ptc1	B-GP
+/-	O
mice	B-OG
both	O
at	O
(	O
A	O
)	O
P1	O
and	O
(	O
D	O
)	O
P7	O
.	O
(	O
B	O
and	O
E	O
)	O
H	O
&	O
E	O
stained	O
sagittal	O
sections	O
of	O
Ptc1	B-GP
+/-	O
and	O
(	O
C	O
and	O
F	O
)	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
cerebellum	O
at	O
P1	O
and	O
P7	O
.	O

The	O
number	O
of	O
mice	B-OG
used	O
per	O
test	O
is	O
indicated	O
in	O
the	O
graph	O
(	O
n	O
).	O
*	O
P	O
≤	O
0	O
.	O
05	O
;	O
**	O
P	O
≤	O
0	O
.	O
005	O
;	O
***	O
P	O
≤	O
0	O
.	O
0001	O
.	O

Proliferation	O
,	O
DNA	O
damage	O
and	O
cell	O
death	O
in	O
CGNPs	O
of	O
cerebellum	O
in	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
double	O
mutants	O

We	O
next	O
analyzed	O
the	O
cellular	O
mechanisms	O
underlying	O
synthetic	O
lethal	O
interactions	O
between	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
by	O
focusing	O
on	O
the	O
cerebellum	O
of	O
Ptc1	B-GP
+/-	O
mutants	O
.	O

The	O
neonatal	O
cerebellum	O
undergoes	O
rapid	O
postnatal	O
development	O
,	O
occurring	O
through	O
a	O
burst	O
of	O
proliferation	O
of	O
granule	O
cell	O
precursors	O
(	O
GCPs	O
)	O
in	O
the	O
external	O
granule	O
layer	O
(	O
EGL	O
)	O
on	O
the	O
cerebellar	O
surface	O
.	O

Notably	O
,	O
highly	O
proliferating	O
cells	O
are	O
particularly	O
susceptible	O
to	O
endogenous	O
and	O
exogenous	O
DNA	O
damage	O
,	O
due	O
to	O
the	O
presence	O
of	O
numerous	O
replication	O
forks	O
that	O
may	O
stall	O
and	O
eventually	O
undergo	O
DSBs	O
after	O
collision	O
with	O
DNA	O
damage	O
[	O
25	O
,	O
26	O
].	O

This	O
makes	O
this	O
cellular	O
population	O
suitable	O
for	O
investigating	O
DNA	O
repair	O
-	O
related	O
mechanisms	O
responsible	O
for	O
the	O
growth	O
delay	O
observed	O
.	O

Quantification	O
of	O
Ki	B-GP
-	I-GP
67	I-GP
staining	O
in	O
the	O
EGL	O
revealed	O
a	O
high	O
proliferation	O
rate	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
Figure	O
4A	O
-	O
4E	O
),	O
which	O
is	O
in	O
keeping	O
with	O
the	O
higher	O
spontaneous	O
MB	B-DS
tumorigenesis	O
detected	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
mice	B-OG
.	O

Similarly	O
high	O
growth	O
rates	O
were	O
not	O
observed	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
suggesting	O
that	O
persistent	O
SSBs	O
formation	O
due	O
to	O
Parp	B-GP
-	I-GP
1	I-GP
inhibition	O
,	O
promoting	O
collapse	O
of	O
replication	O
forks	O
and	O
DSBs	O
which	O
would	O
normally	O
be	O
repaired	O
by	O
HR	O
,	O
cannot	O
be	O
repaired	O
effectively	O
in	O
the	O
absence	O
of	O
functional	O
Rad54	B-GP
.	O

Evaluation	O
of	O
proliferation	O
,	O
DNA	O
damage	O
and	O
cell	O
death	O
in	O
neuronal	O
precursors	O
of	O
the	O
EGL	O
at	O
P1	O
and	O
differentiation	O
in	O
mature	O
granule	O
neurons	O
in	O
the	O
IGL	O
at	O
P7	O

(	O
A	O
-	O
E	O
)	O
Immunohistochemical	O
analyses	O
for	O
Ki	B-GP
-	I-GP
67	I-GP
showing	O
significant	O
increased	O
expression	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
compared	O
to	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O
(	O
F	O
-	O
J	O
)	O
Immunohistochemical	O
analyses	O
for	O
γ	O
-	O
H2AX	B-GP
showing	O
significantly	O
increased	O
expression	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
compared	O
to	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O
(	O
K	O
-	O
O	O
)	O
Immunohistochemical	O
analyses	O
for	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
(	O
CC3	B-GP
)	O
showing	O
significantly	O
increased	O
expression	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
compared	O
to	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
or	O
Ptc1	B-GP
+/-	O
mutant	O
mice	B-OG
.	O
(	O
P	O
)	O
The	O
ratio	O
between	O
EGL	O
and	O
IGL	O
area	O
was	O
similar	O
in	O
mice	B-OG
of	O
all	O
genotypes	O
.	O
(	O
Q	O
)	O
Significant	O
decrease	O
in	O
number	O
of	O
mature	O
neurons	O
expressing	O
NeuN	B-GP
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mutants	O
compared	O
to	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O
(	O
R	O
and	O
S	O
)	O
Expression	O
level	O
of	O
NeuN	B-GP
was	O
determined	O
in	O
a	O
fixed	O
area	O
(	O
in	O
red	O
)	O
from	O
folia	O
VIII	O
.	O

The	O
number	O
of	O
mice	B-OG
used	O
per	O
test	O
is	O
indicated	O
in	O
the	O
graph	O
(	O
n	O
).	O
*	O
P	O
≤	O
0	O
.	O
05	O
;	O
**	O
P	O
≤	O
0	O
.	O
005	O
;	O
***	O
P	O
≤	O
0	O
.	O
0001	O
.	O

We	O
therefore	O
evaluated	O
whether	O
concomitant	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
enhances	O
DNA	O
damage	O
and	O
apoptosis	O
in	O
the	O
neural	O
precursor	O
population	O
of	O
the	O
EGL	O
of	O
double	O
-	O
compared	O
to	O
single	O
-	O
mutants	O
or	O
wt	O
mice	B-OG
.	O

To	O
this	O
aim	O
,	O
P1	O
brains	O
were	O
immunostained	O
with	O
a	O
DSB	O
(	O
γ	O
-	O
H2AX	B-GP
),	O
or	O
an	O
apoptotic	O
marker	O
(	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
),	O
and	O
the	O
staining	O
in	O
the	O
EGL	O
was	O
quantified	O
.	O

Consistent	O
with	O
its	O
recognized	O
role	O
in	O
resolution	O
of	O
SSB	O
and	O
stalled	O
replication	O
forks	O
,	O
inactivation	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
,	O
but	O
not	O
Rad54	B-GP
,	O
resulted	O
in	O
a	O
significant	O
3	O
-	O
fold	O
increase	O
of	O
spontaneous	O
DSBs	O
compared	O
to	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
P	O
=	O
0	O
.	O
0013	O
).	O

A	O
4	O
-	O
fold	O
increase	O
(	O
P	O
=	O
0	O
.	O
0010	O
)	O
was	O
also	O
detected	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mutants	O
(	O
Figure	O
4F	O
-	O
4J	O
).	O

However	O
,	O
despite	O
similar	O
amount	O
of	O
DSBs	O
induced	O
by	O
inactivation	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
and	O
by	O
combined	O
inactivation	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
and	O
Rad54	B-GP
,	O
we	O
detected	O
large	O
differences	O
in	O
positivity	O
for	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
among	O
the	O
different	O
mutants	O
(	O
Figure	O
4K	O
-	O
4O	O
).	O

Mice	B-OG
with	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
(	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-)	O
showed	O
significantly	O
increased	O
staining	O
for	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
expression	O
compared	O
to	O
Rad54	B-GP
-/-	O
(	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-;	O
15	O
.	O
3	O
-	O
fold	O
,	O
P	O
=	O
0	O
.	O
007	O
),	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
(	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-;	O
3	O
.	O
9	O
-	O
fold	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
or	O
Ptc1	B-GP
+/-	O
(	O
Ptc1	B-GP
+/-;	O
9	O
.	O
3	O
-	O
fold	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
mice	B-OG
.	O

These	O
findings	O
confirm	O
that	O
Parp	B-GP
-	I-GP
1	I-GP
inactivation	O
causes	O
an	O
excess	O
of	O
spontaneous	O
DSBs	O
in	O
neural	O
cells	O
,	O
which	O
can	O
be	O
partly	O
repaired	O
if	O
Rad54	B-GP
is	O
active	O
,	O
but	O
result	O
in	O
high	O
apoptotic	O
levels	O
in	O
GCPs	O
with	O
concurrent	O
Rad54	B-GP
inactivation	O
.	O

In	O
the	O
neonatal	O
cerebellum	O
,	O
the	O
proliferation	O
phase	O
is	O
followed	O
by	O
differentiation	O
processes	O
,	O
consisting	O
in	O
cell	O
cycle	O
exit	O
and	O
inward	O
migration	O
of	O
postmitotic	O
GCPs	O
to	O
the	O
internal	O
granule	O
layer	O
(	O
IGL	O
),	O
which	O
causes	O
progressive	O
EGL	O
disappearance	O
and	O
formation	O
of	O
the	O
IGL	O
of	O
mature	O
granule	O
neurons	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
on	O
differentiation	O
processes	O
,	O
we	O
measured	O
the	O
areas	O
of	O
the	O
EGL	O
and	O
IGL	O
in	O
the	O
cerebellum	O
of	O
Ptc1	B-GP
+/-	O
mice	B-OG
with	O
single	O
or	O
combined	O
inactivation	O
of	O
Rad54	B-GP
or	O
Parp	B-GP
-	I-GP
1	I-GP
at	O
P7	O
,	O
and	O
calculated	O
their	O
ratio	O
.	O

Despite	O
drastic	O
decrease	O
in	O
cerebellum	O
size	O
,	O
no	O
modification	O
of	O
the	O
EGL	O
/	O
IGL	O
ratio	O
was	O
detected	O
in	O
mice	B-OG
with	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
relative	O
to	O
other	O
genotypes	O
,	O
indicating	O
no	O
overt	O
alterations	O
in	O
the	O
balance	O
between	O
proliferation	O
(	O
EGL	O
)	O
and	O
differentiation	O
(	O
IGL	O
)	O
in	O
the	O
cerebellum	O
caused	O
by	O
single	O
or	O
combined	O
inactivation	O
of	O
the	O
genes	O
under	O
investigation	O
(	O
Figure	O
4P	O
).	O

However	O
,	O
quantification	O
of	O
the	O
density	O
of	O
neurons	O
labeled	O
by	O
the	O
NeuN	B-GP
marker	O
of	O
mature	O
neurons	O
in	O
fixed	O
regions	O
of	O
the	O
IGL	O
(	O
crest	O
number	O
VIII	O
,	O
red	O
square	O
in	O
Figure	O
4R	O
and	O
4S	O
),	O
revealed	O
a	O
significant	O
decrease	O
in	O
the	O
density	O
of	O
NeuN	B-GP
+	O
mature	O
neurons	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
(	O
43	O
.	O
5	O
%,	O
P	O
=	O
0	O
.	O
0126	O
)	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
45	O
.	O
7	O
%,	O
P	O
=	O
0	O
.	O
0042	O
),	O
suggestive	O
of	O
depletion	O
of	O
granule	O
neurons	O
(	O
Figure	O
4Q	O
and	O
4S	O
).	O

Synthetic	O
lethality	O
affects	O
the	O
expression	O
of	O
DNA	O
repair	O
related	O
gene	O

The	O
robust	O
synthetic	O
lethal	O
effect	O
of	O
combined	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inactivating	O
mutations	O
led	O
us	O
to	O
investigate	O
the	O
underlying	O
molecular	O
mechanisms	O
by	O
addressing	O
the	O
modification	O
of	O
the	O
expression	O
profile	O
of	O
84	O
genes	O
with	O
established	O
roles	O
in	O
DNA	O
damage	O
signaling	O
.	O

We	O
carried	O
out	O
this	O
analysis	O
in	O
the	O
P1	O
cerebellum	O
of	O
Ptc1	B-GP
+/-	O
mice	B-OG
with	O
single	O
or	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
/	O
or	O
Parp	B-GP
-	I-GP
1	I-GP
(	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-)	O
and	O
results	O
were	O
compared	O
with	O
those	O
from	O
Ptc1	B-GP
+/-	O
mice	B-OG
using	O
a	O
pathway	O
-	O
based	O
PCR	O
expression	O
array	O
.	O

In	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
14	O
genes	O
were	O
significantly	O
downregulated	O
(	O
16	O
.	O
7	O
%)	O
and	O
8	O
upregulated	O
(	O
9	O
.	O
5	O
%);	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
22	O
genes	O
were	O
significantly	O
downregulated	O
(	O
26	O
%)	O
and	O
6	O
(	O
7	O
%)	O
upregulated	O
;	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
10	O
genes	O
(	O
12	O
%)	O
were	O
downregulated	O
and	O
16	O
(	O
19	O
%)	O
upregulated	O
(	O
S1	O
Table	O
).	O

The	O
magnitude	O
of	O
many	O
of	O
these	O
changes	O
was	O
small	O
.	O

However	O
,	O
as	O
DNA	O
repair	O
genes	O
are	O
expressed	O
at	O
basal	O
level	O
in	O
mammals	B-OG
,	O
detection	O
of	O
small	O
changes	O
does	O
not	O
necessarily	O
mean	O
a	O
negligible	O
biological	O
significance	O
,	O
but	O
rather	O
that	O
even	O
slight	O
deregulation	O
may	O
significantly	O
modify	O
DNA	O
repair	O
capacity	O
.	O

We	O
also	O
performed	O
a	O
hierarchical	O
clustering	O
analysis	O
that	O
produced	O
different	O
groups	O
of	O
genes	O
(	O
colored	O
bars	O
,	O
left	O
side	O
)	O
based	O
on	O
similar	O
fold	O
-	O
change	O
patterns	O
among	O
the	O
three	O
genotypes	O
(	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
)	O
(	O
Figure	O
5A	O
).	O

In	O
particular	O
,	O
the	O
violet	O
module	O
(	O
lowest	O
bar	O
)	O
shows	O
the	O
most	O
upregulated	O
genes	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
i	O
.	O
e	O
.,	O
Exo1	B-GP
,	O
P	O
=	O
0	O
.	O
031	O
;	O
Pttg1	B-GP
,	O
P	O
=	O
0	O
.	O
001	O
);	O
in	O
the	O
gray	O
module	O
are	O
listed	O
the	O
genes	O
downregulated	O
in	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mutants	O
that	O
are	O
upregulated	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
of	O
which	O
Xpa	B-GP
was	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
033	O
);	O
instead	O
,	O
in	O
the	O
red	O
module	O
,	O
the	O
synergistic	O
effects	O
of	O
combined	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
mutations	O
lead	O
to	O
downregulation	O
of	O
several	O
genes	O
(	O
i	O
.	O
e	O
.,	O
Atm	B-GP
,	O
P	O
=	O
0	O
.	O
031	O
;	O
Atr	B-GP
,	O
P	O
=	O
0	O
.	O
008	O
;	O
Atrx	B-GP
,	O
P	O
=	O
0	O
.	O
006	O
;	O
Parp	B-GP
-	I-GP
1	I-GP
,	O
P	O
=	O
0	O
.	O
001	O
;	O
Prkdc	B-GP
,	O
P	O
=	O
0	O
.	O
029	O
;	O
Rad50	B-GP
,	O
P	O
=	O
0	O
.	O
028	O
;	O
Wrn	B-GP
,	O
P	O
=	O
0	O
.	O
016	O
)	O
(	O
Figure	O
5A	O
and	O
Table	O
S1	O
).	O

Bioinformatic	O
analysis	O
of	O
expression	O
profiles	O
of	O
DNA	O
repair	O
-	O
related	O
genes	O
in	O
P1	O
cerebella	O
from	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Ptc1	B-GP
+/-	O
mice	B-OG

(	O
A	O
)	O
Heat	O
map	O
,	O
generated	O
from	O
RT2	O
Profiler	O
PCR	O
Arrays	O
Mouse	B-OG
DNA	O
Damage	O
,	O
representing	O
the	O
fold	O
-	O
change	O
variation	O
in	O
the	O
three	O
genotypes	O
(	O
solid	O
blue	O
lines	O
)	O
versus	O
the	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
dotted	O
blue	O
lines	O
).	O

Relative	O
hierarchical	O
clustered	O
groups	O
represented	O
by	O
colored	O
bars	O
on	O
left	O
side	O
.	O
(	O
B	O
)	O
Gene	O
Ontology	O
network	O
generated	O
by	O
analysis	O
of	O
the	O
most	O
significantly	O
perturbed	O
KEGG	O
pathways	O
in	O
the	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
when	O
compared	O
to	O
the	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O
(	O
C	O
)	O
SYBR	O
Green	O
real	O
-	O
time	O
PCR	O
validation	O
of	O
ATM	B-GP
and	O
Prkdc	B-GP
(	O
DNA	B-GP
-	I-GP
PKcs	I-GP
)	O
genes	O
.	O
(	O
D	O
)	O
Immunoblot	O
analysis	O
of	O
ATM	B-GP
and	O
DNA	B-GP
-	I-GP
PKcs	I-GP
proteins	O
with	O
relative	O
HSP70	B-GP
as	O
loading	O
control	O
.	O
*	O
P	O
≤	O
0	O
.	O
05	O
;	O
**	O
P	O
≤	O
0	O
.	O
005	O
;	O
***	O
P	O
≤	O
0	O
.	O
0001	O
.	O

Pathway	O
analysis	O
of	O
all	O
significantly	O
deregulated	O
genes	O
was	O
performed	O
using	O
SPIA	O
algorithm	O
.	O

The	O
signaling	O
pathway	O
showing	O
a	O
significant	O
perturbation	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
was	O
the	O
“	O
Cell	O
Cycle	O
”	O
pathway	O
,	O
including	O
10	O
genes	O
(	O
i	O
.	O
e	O
.	O
Atm	B-GP
,	O
Cdc25c	B-GP
,	O
Cdkn1a	B-GP
,	O
Pcna	B-GP
,	O
Prkdc	B-GP
,	O
Rad21	B-GP
,	O
Gadd45g	B-GP
,	O
Smc1a	B-GP
,	O
Atr	B-GP
,	O
Pttg1	B-GP
)	O
with	O
fold	O
changes	O
and	O
topological	O
distribution	O
suggesting	O
pathway	O
inhibition	O
.	O

Further	O
analysis	O
of	O
these	O
genes	O
,	O
performed	O
with	O
the	O
Cytoscape	O
gene	O
ontology	O
tool	O
Cluego	O
,	O
showed	O
a	O
substantial	O
overlap	O
with	O
the	O
p53	B-GP
signaling	O
pathway	O
(	O
Figure	O
5B	O
).	O

We	O
validated	O
Atm	B-GP
and	O
Prkdc	B-GP
(	O
DNA	B-GP
-	I-GP
PKcs	I-GP
),	O
by	O
RT	O
-	O
PCR	O
confirming	O
a	O
significantly	O
decreased	O
expression	O
in	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
compound	O
mutants	O
(	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-)	O
compared	O
to	O
single	O
mutants	O
(	O
Figure	O
5C	O
)	O
and	O
verified	O
the	O
decreased	O
expression	O
levels	O
of	O
ATM	B-GP
and	O
DNA	B-GP
-	I-GP
PKcs	I-GP
by	O
immunoblotting	O
(	O
Figure	O
5D	O
).	O

p53	B-GP
/	O
p21	B-GP
-	O
mediated	O
senescence	O
as	O
underlying	O
mechanism	O
for	O
the	O
lethal	O
phenotype	O
of	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
compound	O
mutants	O

Based	O
on	O
results	O
of	O
bioinformatic	O
analysis	O
,	O
we	O
analyzed	O
p53	B-GP
expression	O
in	O
protein	O
extracts	O
from	O
P1	O
-	O
cerebellum	O
by	O
immunoblotting	O
.	O

Although	O
no	O
significant	O
differences	O
were	O
detected	O
between	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
single	O
and	O
compound	O
mutants	O
in	O
phosphorylation	O
of	O
p53	B-GP
at	O
Ser18	O
[	O
27	O
],	O
we	O
observed	O
a	O
significant	O
increase	O
in	O
total	O
p53	B-GP
expression	O
(	O
3	O
-	O
fold	O
)	O
only	O
in	O
compound	O
mutants	O
,	O
indicating	O
marked	O
p53	B-GP
activation	O
(	O
Figure	O
6A	O
),	O
which	O
is	O
consistent	O
with	O
persistent	O
genetic	O
damage	O
.	O

We	O
also	O
show	O
that	O
p53	B-GP
stabilization	O
did	O
not	O
occur	O
at	O
transcriptional	O
level	O
,	O
as	O
no	O
changes	O
in	O
the	O
expression	O
of	O
p53	B-GP
were	O
detected	O
in	O
the	O
array	O
(	O
Figure	O
5A	O
and	O
Table	O
S1	O
),	O
suggesting	O
,	O
instead	O
,	O
posttranslational	O
modification	O
.	O

Immunoblotting	O
for	O
p21	B-GP
showed	O
a	O
trend	O
towards	O
increased	O
expression	O
that	O
,	O
however	O
,	O
was	O
not	O
significant	O
(	O
Figure	O
6A	O
).	O

Evaluation	O
of	O
biomarkers	O
of	O
senescence	O

(	O
A	O
)	O
Immunoblot	O
and	O
densitometric	O
analysis	O
of	O
p53	B-GP
/	O
p21	B-GP
signaling	O
[	O
total	O
p53	B-GP
,	O
p53	B-GP
-	O
P	O
(	O
ser18	O
)	O
and	O
p21	B-GP
]	O
in	O
cerebellum	O
of	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-,	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
at	O
P1	O
,	O
and	O
(	O
B	O
)	O
in	O
MEFs	O
from	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
two	O
independent	O
cell	O
lines	O
per	O
genotype	O
);	O
β	B-GP
-	I-GP
actin	I-GP
and	O
HSP70	B-GP
were	O
used	O
as	O
loading	O
controls	O
.	O
(	O
C	O
)	O
Growth	O
kinetics	O
and	O
(	O
D	O
)	O
quantification	O
of	O
SA	O
-	O
β	B-GP
-	I-GP
GAL	I-GP
staining	O
in	O
MEFs	O
from	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mouse	B-OG
embryos	O
.	O
(	O
E	O
)	O
Representative	O
images	O
of	O
SA	O
-	O
β	B-GP
-	I-GP
GAL	I-GP
staining	O
in	O
MEFs	O
from	O
Ptc1	B-GP
+/-,	O
and	O
(	O
F	O
)	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mouse	B-OG
embryos	O
.	O
(	O
G	O
-	O
L	O
)	O
Proliferation	O
(	O
Ki67	B-GP
)	O
and	O
(	O
M	O
-	O
R	O
)	O
DNA	O
damage	O
(	O
γ	O
-	O
H2AX	B-GP
)	O
in	O
different	O
tissues	O
from	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
neonatal	O
mice	B-OG
at	O
P1	O
.	O

The	O
number	O
of	O
mice	B-OG
used	O
per	O
test	O
is	O
indicated	O
in	O
the	O
graph	O
(	O
n	O
).	O
*	O
P	O
≤	O
0	O
.	O
05	O
;	O
**	O
P	O
≤	O
0	O
.	O
005	O
;	O
***	O
P	O
≤	O
0	O
.	O
0001	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
combined	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
mutations	O
at	O
organismal	O
level	O
,	O
we	O
established	O
mouse	B-OG
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
from	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O

Immunoblot	O
analysis	O
of	O
p53	B-GP
/	O
p21	B-GP
signaling	O
pathway	O
in	O
MEFs	O
of	O
different	O
genotypes	O
showed	O
significantly	O
increased	O
expression	O
of	O
p53	B-GP
-	O
P	O
(	O
ser18	O
),	O
p53	B-GP
and	O
p21	B-GP
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mutants	O
compared	O
to	O
Ptc1	B-GP
+/-	O
MEFs	O
(	O
Figure	O
6B	O
).	O

Moreover	O
,	O
MEFs	O
from	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
showed	O
decreased	O
cell	O
growth	O
potential	O
compared	O
to	O
those	O
from	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O

The	O
difference	O
in	O
growth	O
rate	O
become	O
significant	O
at	O
72	O
and	O
96	O
h	O
after	O
seeding	O
,	O
with	O
a	O
1	O
.	O
5	O
-	O
2	O
fold	O
reduction	O
in	O
cell	O
numbers	O
and	O
an	O
increase	O
in	O
doubling	O
times	O
(	O
23	O
vs	O
35	O
h	O
)	O
in	O
MEFs	O
from	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
compared	O
to	O
those	O
from	O
Ptc1	B-GP
+/-	O
mice	B-OG
(	O
Figure	O
6C	O
).	O

We	O
also	O
detected	O
a	O
significantly	O
greater	O
fraction	O
of	O
positive	O
cells	O
after	O
staining	O
with	O
Senescence	O
-	O
Associated	O
β	B-GP
-	I-GP
Galactosidase	I-GP
(	O
SA	O
-	O
β	B-GP
-	I-GP
GAL	I-GP
)	O
(	O
1	O
.	O
6	O
-	O
fold	O
;	O
P	O
=	O
0	O
.	O
048	O
),	O
a	O
biomarker	O
of	O
senescent	O
cells	O
,	O
accompanied	O
by	O
senescence	O
-	O
associated	O
morphological	O
cellular	O
changes	O
(	O
i	O
.	O
e	O
.,	O
enlargement	O
and	O
flattening	O
)	O
(	O
Figure	O
6E	O
and	O
6F	O
),	O
suggesting	O
accelerated	O
acquisition	O
of	O
senescence	O
in	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
compared	O
to	O
Ptc1	B-GP
+/-	O
MEFs	O
.	O

Although	O
identification	O
of	O
senescent	O
cells	O
is	O
challenging	O
,	O
especially	O
in	O
vivo	O
,	O
loss	O
of	O
replicative	O
markers	O
such	O
as	O
Ki	B-GP
-	I-GP
67	I-GP
and	O
sustained	O
DNA	O
damage	O
are	O
often	O
considered	O
as	O
bona	O
fide	O
markers	O
of	O
senescence	O
.	O

We	O
immunostained	O
several	O
tissues	O
(	O
thymus	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
intestine	O
,	O
skin	O
)	O
from	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Ptc1	B-GP
+/-	O
mice	B-OG
at	O
P1	O
with	O
Ki	B-GP
-	I-GP
67	I-GP
and	O
γ	O
-	O
H2AX	B-GP
.	O

Compared	O
to	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
we	O
observed	O
a	O
general	O
decrease	O
in	O
proliferation	O
and	O
increase	O
in	O
DNA	O
damage	O
in	O
all	O
tissues	O
from	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
particularly	O
in	O
thymus	O
,	O
intestine	O
and	O
kidneys	O
(	O
Figure	O
6G	O
-	O
6R	O
).	O

Instead	O
,	O
immunostaining	O
with	O
caspase	B-GP
-	I-GP
3	I-GP
did	O
not	O
reveal	O
obvious	O
differences	O
in	O
apoptosis	O
(	O
data	O
not	O
shown	O
).	O

Altogether	O
,	O
these	O
data	O
strongly	O
support	O
the	O
involvement	O
of	O
p53	B-GP
/	O
p21	B-GP
-	O
mediated	O
accelerated	O
senescence	O
in	O
growth	O
delay	O
of	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
compound	O
mutants	O
,	O
culminating	O
in	O
a	O
lethal	O
perinatal	O
phenotype	O
.	O

DISCUSSION	O

The	O
DNA	O
repair	O
system	O
functions	O
as	O
a	O
critical	O
tumor	B-DS
suppressor	O
network	O
to	O
preserve	O
the	O
integrity	O
of	O
the	O
genome	O
preventing	O
malignancy	O
,	O
and	O
DNA	O
repair	O
defects	O
are	O
frequently	O
encountered	O
in	O
human	B-OG
cancer	B-DS
.	O

Therefore	O
,	O
gaining	O
insights	O
into	O
the	O
mechanism	O
of	O
action	O
of	O
DNA	O
repair	O
genes	O
is	O
pivotal	O
to	O
development	O
of	O
novel	O
tumor	B-DS
-	O
specific	O
treatment	O
strategies	O
targeting	O
deregulated	O
DNA	O
repair	O
[	O
28	O
].	O

A	O
major	O
obstacle	O
to	O
achieving	O
synthetic	O
lethal	O
therapies	O
is	O
a	O
lack	O
of	O
insight	O
into	O
the	O
phenomenon	O
in	O
cancer	B-DS
cells	O
,	O
and	O
insufficient	O
knowledge	O
of	O
the	O
molecular	O
mechanisms	O
influencing	O
synthetic	O
lethal	O
interactions	O
.	O

We	O
earlier	O
investigated	O
in	O
vivo	O
genetic	O
interactions	O
between	O
Parp	B-GP
-	I-GP
1	I-GP
and	O
Ptc1	B-GP
,	O
and	O
found	O
that	O
combined	O
inactivation	O
of	O
the	O
two	O
genes	O
is	O
not	O
critically	O
important	O
for	O
normal	O
development	O
and	O
survival	O
of	O
the	O
compound	O
mutant	O
mice	B-OG
;	O
however	O
,	O
increased	O
genetic	O
instability	O
caused	O
by	O
abrogation	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
was	O
able	O
to	O
promote	O
MB	B-DS
formation	O
in	O
Ptc1	B-GP
+/-	O
mice	B-OG
by	O
fostering	O
accumulation	O
of	O
genetic	O
defects	O
and	O
facilitation	O
of	O
loss	O
of	O
the	O
remaining	O
normal	O
Ptc1	B-GP
allele	O
[	O
22	O
].	O

Despite	O
the	O
critical	O
role	O
of	O
the	O
HR	O
system	O
for	O
embryonic	O
development	O
,	O
attenuated	O
HR	O
by	O
deletion	O
of	O
Rad54	B-GP
also	O
did	O
not	O
result	O
in	O
lethality	O
in	O
Ptc1	B-GP
+/-	O
mice	B-OG
,	O
implying	O
redundancy	O
in	O
function	O
of	O
proteins	O
involved	O
in	O
HR	O
;	O
however	O
,	O
in	O
previous	O
work	O
,	O
by	O
exposing	O
double	O
Rad54	B-GP
/	O
Ptc1	B-GP
mutants	O
to	O
2	O
Gy	O
,	O
we	O
detected	O
significantly	O
increased	O
MB	B-DS
tumorigenesis	O
,	O
possibly	O
through	O
the	O
generation	O
of	O
viable	O
but	O
genetically	O
rearranged	O
neural	O
cell	O
precursors	O
due	O
to	O
repair	O
of	O
DNA	O
lesions	O
by	O
error	O
-	O
prone	O
mutagenic	O
pathways	O
[	O
21	O
].	O

An	O
analogous	O
increase	O
was	O
not	O
seen	O
here	O
,	O
likely	O
due	O
to	O
the	O
lower	O
dose	O
used	O
and	O
relative	O
radioresistance	O
of	O
Rad54	B-GP
-/-	O
mice	B-OG
[	O
23	O
].	O

Former	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
Parp	B-GP
-	I-GP
1	I-GP
inhibitors	O
induce	O
synthetic	O
lethality	O
in	O
cells	O
that	O
are	O
defective	O
in	O
HR	O
[	O
1	O
,	O
2	O
,	O
29	O
].	O

An	O
extensive	O
body	O
of	O
literature	O
has	O
since	O
documented	O
the	O
impact	O
of	O
Parp	B-GP
inhibitors	O
on	O
synthetic	O
lethality	O
in	O
cells	O
that	O
are	O
defective	O
in	O
HR	O
due	O
to	O
loss	O
of	O
HR	O
-	O
associated	O
proteins	O
,	O
and	O
their	O
use	O
as	O
single	O
-	O
agent	O
therapies	O
acting	O
through	O
the	O
concept	O
of	O
synthetic	O
lethality	O
[	O
30	O
].	O

The	O
results	O
shown	O
here	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
Parp	B-GP
-	I-GP
1	I-GP
and	O
Rad54	B-GP
are	O
genetically	O
linked	O
and	O
that	O
they	O
share	O
overlapping	O
functions	O
that	O
are	O
essential	O
in	O
mouse	B-OG
development	O
.	O

We	O
observed	O
not	O
only	O
that	O
the	O
combination	O
is	O
active	O
in	O
vivo	O
,	O
but	O
could	O
also	O
clarify	O
that	O
Parp	B-GP
-	I-GP
1	I-GP
is	O
not	O
strictly	O
necessary	O
for	O
HR	O
during	O
early	O
embryogenesis	O
,	O
as	O
combined	O
deletions	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
and	O
Rad54	B-GP
caused	O
significantly	O
reduced	O
birth	O
rate	O
and	O
growth	O
retardation	O
-	O
resulting	O
in	O
early	O
death	O
of	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
pups	O
-	O
not	O
full	O
embryonic	O
lethality	O
.	O

Since	O
evaluation	O
of	O
the	O
effects	O
of	O
simultaneous	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inactivation	O
on	O
MB	B-DS
development	O
was	O
prevented	O
by	O
the	O
lack	O
of	O
viable	O
compound	O
mutants	O
,	O
we	O
investigated	O
the	O
inactivation	O
of	O
DNA	O
repair	O
genes	O
in	O
the	O
context	O
of	O
Ptc1	B-GP
tumor	B-DS
suppression	O
by	O
examining	O
mice	B-OG
with	O
complete	O
abrogation	O
of	O
either	O
Rad54	B-GP
or	O
Parp	B-GP
-	I-GP
1	I-GP
function	O
,	O
in	O
combination	O
with	O
heterozygosis	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
or	O
Rad54	B-GP
,	O
respectively	O
.	O

Attenuation	O
of	O
Rad54	B-GP
in	O
the	O
context	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
abrogation	O
had	O
synthetic	O
lethal	O
effects	O
in	O
dosage	O
-	O
independent	O
manner	O
.	O

In	O
contrast	O
,	O
inactivation	O
of	O
one	O
copy	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
the	O
setting	O
of	O
Rad54	B-GP
abrogation	O
had	O
two	O
distinct	O
outcomes	O
depending	O
on	O
treatment	O
,	O
i	O
.	O
e	O
.,	O
no	O
effect	O
on	O
spontaneous	O
tumor	B-DS
development	O
,	O
or	O
decreased	O
induction	O
of	O
MB	B-DS
induced	O
by	O
radiation	O
.	O

A	O
further	O
increase	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
inactivation	O
(	O
i	O
.	O
e	O
.,	O
both	O
copies	O
)	O
caused	O
a	O
shift	O
to	O
synthetic	O
lethality	O
(	O
i	O
.	O
e	O
.,	O
loss	O
of	O
viable	O
progeny	O
),	O
demonstrating	O
that	O
combined	O
defects	O
in	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
cause	O
synthetic	O
lethal	O
interactions	O
in	O
a	O
Parp	B-GP
-	I-GP
1	I-GP
-	O
gene	O
dosage	O
dependent	O
manner	O
,	O
and	O
highlighting	O
the	O
delicate	O
balance	O
that	O
must	O
be	O
hit	O
when	O
targeting	O
essential	O
pathways	O
.	O

Important	O
to	O
our	O
understanding	O
of	O
the	O
underlying	O
mechanisms	O
of	O
this	O
novel	O
genetic	O
link	O
,	O
immunohistochemical	O
analysis	O
revealed	O
a	O
trend	O
to	O
high	O
degree	O
of	O
granule	O
cell	O
proliferation	O
in	O
the	O
EGL	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
null	O
mice	B-OG
(	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-),	O
which	O
decreased	O
significantly	O
in	O
age	O
-	O
matched	O
double	O
mutants	O
(	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-).	O

This	O
was	O
accompanied	O
by	O
substantial	O
delay	O
in	O
neuronal	O
differentiation	O
,	O
as	O
shown	O
by	O
sparse	O
NeuN	B-GP
staining	O
and	O
limited	O
presence	O
of	O
committed	O
GCPs	O
in	O
both	O
groups	O
.	O

Given	O
the	O
concurrent	O
high	O
levels	O
of	O
spontaneous	O
DSBs	O
in	O
both	O
Parp	B-GP
-	I-GP
1	I-GP
null	O
mutants	O
(	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-),	O
the	O
low	O
apoptotic	O
levels	O
observed	O
only	O
in	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
correlate	O
well	O
with	O
the	O
high	O
spontaneous	O
rate	O
of	O
MB	B-DS
in	O
these	O
mice	B-OG
,	O
and	O
suggest	O
that	O
the	O
cells	O
can	O
survive	O
with	O
a	O
mutation	O
in	O
either	O
repair	O
pathways	O
,	O
not	O
both	O
,	O
which	O
causes	O
cells	O
to	O
die	O
.	O

As	O
several	O
DNA	B-DS
repair	I-DS
deficiency	I-DS
syndromes	I-DS
(	O
e	O
.	O
g	O
.	O
ataxia	B-DS
telangiectasia	I-DS
,	O
and	O
spinocerebellar	B-DS
ataxia	I-DS
with	O
axonal	B-DS
neuropathy1	I-DS
)	O
target	O
the	O
cerebellum	O
[	O
31	O
],	O
we	O
set	O
up	O
to	O
investigate	O
how	O
alternative	O
repair	O
pathways	O
compensate	O
the	O
impairment	O
of	O
predominant	O
DNA	O
repair	O
mechanisms	O
to	O
maintain	O
cerebellum	O
integrity	O
.	O

We	O
compared	O
gene	O
expression	O
changes	O
in	O
DNA	O
repair	O
-	O
related	O
genes	O
in	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
single	O
(	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-;	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-)	O
and	O
combined	O
mutants	O
(	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-)	O
versus	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O

We	O
detected	O
strong	O
downregulation	O
of	O
Prkdc	B-GP
(	O
DNA	B-GP
-	I-GP
PKcs	I-GP
),	O
which	O
was	O
unexpected	O
as	O
DNA	B-GP
-	I-GP
PKcs	I-GP
activation	O
has	O
been	O
invoked	O
to	O
explain	O
the	O
synthetic	O
lethal	O
effects	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
inhibitors	O
in	O
HR	O
-	O
defective	O
cells	O
[	O
32	O
].	O
DNA	B-GP
-	I-GP
PKcs	I-GP
downregulation	O
was	O
paralleled	O
by	O
marked	O
downregulation	O
of	O
Atm	B-GP
.	O
DNA	B-GP
-	I-GP
PKcs	I-GP
and	O
Atm	B-GP
are	O
both	O
members	O
of	O
the	O
phosphatidylinositol	B-GP
3	I-GP
-	I-GP
kinase	I-GP
(	O
PI3K	B-GP
)-	O
related	O
protein	B-GP
kinase	I-GP
superfamily	O
and	O
act	O
in	O
tandem	O
by	O
important	O
cross	O
-	O
talk	O
[	O
33	O
,	O
34	O
].	O

Notably	O
,	O
combined	O
loss	O
of	O
Atm	B-GP
and	O
DNA	B-GP
-	I-GP
PKcs	I-GP
cause	O
embryonic	O
lethality	O
in	O
mice	B-OG
[	O
35	O
,	O
36	O
],	O
suggesting	O
that	O
their	O
downregulation	O
may	O
be	O
central	O
to	O
the	O
perinatal	O
lethality	O
of	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
mutants	O
.	O

PI3K	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inhibitors	O
has	O
proven	O
effective	O
in	O
treating	O
Brca1	B-GP
-	O
related	O
breast	B-DS
cancer	I-DS
in	O
vivo	O
[	O
37	O
].	O

Driven	O
by	O
the	O
results	O
of	O
the	O
bioinformatic	O
analysis	O
converging	O
on	O
p53	B-GP
signaling	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
p53	B-GP
protein	O
in	O
P1	O
-	O
cerebellum	O
and	O
MEFs	O
,	O
detecting	O
significant	O
accumulation	O
of	O
p53	B-GP
protein	O
in	O
both	O
.	O

Because	O
p53	B-GP
phosphorylation	O
is	O
classically	O
considered	O
as	O
the	O
first	O
crucial	O
step	O
of	O
p53	B-GP
stabilization	O
,	O
driven	O
by	O
several	O
kinases	B-GP
,	O
including	O
ATM	B-GP
and	O
DNA	B-GP
-	I-GP
PKcs	I-GP
,	O
we	O
analyzed	O
phosphorylation	O
of	O
p53	B-GP
at	O
Ser18	O
[	O
27	O
]	O
in	O
P1	O
cerebella	O
and	O
did	O
not	O
detect	O
significant	O
differences	O
among	O
genotypes	O
,	O
despite	O
accumulation	O
of	O
p53	B-GP
only	O
in	O
double	O
mutants	O
.	O

However	O
,	O
it	O
is	O
known	O
that	O
multiple	O
phosphorylation	O
sites	O
exist	O
,	O
acting	O
cooperatively	O
for	O
stimulating	O
p53	B-GP
activity	O
[	O
38	O
].	O

Also	O
,	O
phosphorylation	O
may	O
not	O
be	O
a	O
universal	O
requirement	O
for	O
p53	B-GP
stabilization	O
,	O
especially	O
in	O
vivo	O
,	O
as	O
several	O
studies	O
have	O
established	O
,	O
shifting	O
attention	O
on	O
Mdm2	B-GP
regulation	O
of	O
p53	B-GP
[	O
39	O
].	O

All	O
these	O
factors	O
,	O
along	O
with	O
differences	O
between	O
in	O
vitro	O
and	O
in	O
vivo	O
conditions	O
,	O
may	O
concur	O
to	O
explain	O
the	O
differences	O
in	O
the	O
expression	O
pattern	O
of	O
p53	B-GP
/	O
p53	B-GP
Ser18	O
observed	O
between	O
MEFs	O
and	O
cerebellum	O
.	O

Our	O
results	O
of	O
p53	B-GP
expression	O
in	O
P1	O
-	O
cerebellum	O
and	O
MEFs	O
are	O
in	O
line	O
with	O
the	O
fact	O
that	O
deficiency	O
in	O
several	O
DNA	O
repair	O
genes	O
such	O
as	O
DNA	O
Lig4	B-GP
,	O
XRCC4	B-GP
and	O
Rad51	B-GP
cause	O
increased	O
level	O
of	O
genotoxic	O
stress	O
,	O
triggering	O
a	O
p53	B-GP
-	O
dependent	O
DNA	O
damage	O
response	O
leading	O
to	O
embryonic	O
lethality	O
[	O
40	O
–	O
42	O
].	O

More	O
generally	O
,	O
mutations	O
in	O
over	O
150	O
cell	O
-	O
essential	O
genes	O
from	O
different	O
pathways	O
result	O
in	O
recurrent	O
phenotypes	O
,	O
which	O
involve	O
neural	O
apoptosis	O
and	O
developmental	O
delay	O
in	O
zebrafish	B-OG
and	O
share	O
p53	B-GP
upregulation	O
,	O
suggesting	O
that	O
p53	B-GP
might	O
function	O
as	O
a	O
developmental	O
checkpoint	O
triggered	O
by	O
various	O
stressors	O
,	O
including	O
genetic	O
defects	O
[	O
43	O
].	O

In	O
agreement	O
,	O
mice	B-OG
with	O
constitutively	O
active	O
p53	B-GP
are	O
generally	O
not	O
viable	O
,	O
due	O
to	O
inhibition	O
of	O
proliferation	O
-	O
via	O
cell	O
-	O
cycle	O
arrest	O
,	O
quiescence	O
,	O
senescence	O
and	O
differentiation	O
-	O
and	O
/	O
or	O
induction	O
of	O
apoptosis	O
[	O
44	O
].	O

The	O
nature	O
and	O
intensity	O
of	O
damage	O
,	O
as	O
well	O
as	O
,	O
the	O
level	O
of	O
p53	B-GP
expression	O
and	O
its	O
interaction	O
with	O
specific	O
proteins	O
,	O
may	O
determine	O
the	O
choice	O
among	O
the	O
different	O
cellular	O
responses	O
that	O
overall	O
are	O
cell	O
-	O
type	O
specific	O
.	O

Besides	O
p53	B-GP
-	O
dependent	O
neuronal	O
apoptosis	O
,	O
our	O
findings	O
that	O
MEFs	O
from	O
compound	O
Rad54	B-GP
/	O
Parp	B-GP
-	I-GP
1	I-GP
mutant	O
mice	B-OG
display	O
severe	O
p53	B-GP
-	O
mediated	O
accelerated	O
senescent	O
phenotypes	O
,	O
and	O
that	O
features	O
of	O
senescence	O
were	O
detected	O
in	O
several	O
neonatal	O
tissues	O
,	O
strongly	O
argue	O
for	O
senescence	O
as	O
the	O
mechanism	O
underlying	O
synthetic	O
lethal	O
interactions	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
inactivation	O
in	O
vivo	O
.	O

Notably	O
,	O
many	O
of	O
the	O
DNA	O
repair	O
pathways	O
found	O
deregulated	O
in	O
the	O
cerebellum	O
of	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mutants	O
have	O
been	O
reported	O
to	O
cause	O
senescence	O
;	O
overexpression	O
of	O
Pttg1	B-GP
,	O
the	O
most	O
upregulated	O
gene	O
in	O
our	O
settings	O
,	O
induces	O
senescence	O
in	O
a	O
p53	B-GP
-	O
dependent	O
fashion	O
in	O
normal	O
fibroblasts	O
[	O
45	O
],	O
and	O
chemical	O
inhibition	O
of	O
DNA	B-GP
-	I-GP
PKcs	I-GP
leads	O
to	O
p53	B-GP
-	O
dependent	O
accelerated	O
senescence	O
after	O
irradiation	O
in	O
vivo	O
and	O
in	O
vitro	O
[	O
46	O
].	O

In	O
summary	O
,	O
our	O
data	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
interplay	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
vivo	O
by	O
showing	O
that	O
their	O
combined	O
genetic	O
disruption	O
caused	O
a	O
marked	O
growth	O
delay	O
culminating	O
in	O
a	O
perinatal	O
lethal	O
phenotype	O
.	O

We	O
identified	O
accumulation	O
of	O
DNA	O
damage	O
and	O
enhanced	O
apoptotic	O
cell	O
death	O
as	O
a	O
driving	O
mechanism	O
for	O
growth	O
retardation	O
during	O
development	O
of	O
the	O
cerebellum	O
in	O
Rad54	B-GP
/	O
Parp	B-GP
-	I-GP
1	I-GP
compound	O
mutants	O
.	O

Mechanistically	O
,	O
NHEJ	O
was	O
selectively	O
repressed	O
through	O
downregulation	O
of	O
DNA	B-GP
-	I-GP
PKcs	I-GP
.	O

Concomitant	O
downregulation	O
of	O
Atm	B-GP
was	O
also	O
identified	O
,	O
directly	O
involving	O
transcriptional	O
repression	O
of	O
PI3K	B-GP
signaling	O
in	O
synthetic	O
lethality	O
caused	O
by	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
deficiency	O
.	O

Finally	O
,	O
combined	O
inactivation	O
of	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
caused	O
accumulation	O
of	O
p53	B-GP
and	O
p21	B-GP
,	O
which	O
resulted	O
in	O
enhanced	O
senescence	O
in	O
MEFs	O
and	O
several	O
mouse	B-OG
tissues	O
from	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mutants	O
.	O

The	O
p53	B-GP
-	O
depedent	O
apoptotic	O
/	O
senescent	O
phenotypes	O
is	O
also	O
potentially	O
tumor	B-DS
protective	O
;	O
in	O
fact	O
,	O
inactivation	O
of	O
one	O
copy	O
of	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-	O
mutants	O
suppressed	O
radiation	O
-	O
induced	O
MB	B-DS
tumorigenesis	O
,	O
identifying	O
haplosufficient	O
interactions	O
also	O
during	O
neoplastic	O
growth	O
.	O

Investigating	O
the	O
functional	O
interplay	O
between	O
the	O
HR	O
factor	O
Rad54	B-GP
and	O
Parp	B-GP
-	I-GP
1	I-GP
in	O
vivo	O
during	O
development	O
and	O
oncogenesis	O
may	O
help	O
delineate	O
the	O
molecular	O
mechanisms	O
of	O
lethal	O
synthetic	O
interactions	O
and	O
guide	O
more	O
successful	O
clinical	O
translation	O
.	O

MATERIAL	O
AND	O
METHODS	O

Animal	O
breeding	O

Mice	B-OG
lacking	O
one	O
Ptc1	B-GP
allele	O
(	O
Ptc1neo6	O
-	O
7	O
/+,	O
named	O
Ptc1	B-GP
+/-	O
throughout	O
the	O
text	O
)	O
were	O
generated	O
through	O
disruption	O
of	O
exons	O
6	O
and	O
7	O
in	O
129	O
/	O
Sv	O
embryonic	O
stem	O
cells	O
[	O
18	O
],	O
and	O
maintained	O
on	O
CD1	B-GP
background	O
.	O

Genotyping	O
for	O
Ptc1	B-GP
was	O
performed	O
as	O
described	O
[	O
18	O
].	O
Ptc1	B-GP
+/-	O
mice	B-OG
were	O
crossed	O
with	O
Rad54	B-GP
-/-	O
or	O
Parp	B-GP
-	I-GP
1	I-GP
-/-	O
mice	B-OG
on	O
C57Bl	O
/	O
6	O
background	O
[	O
47	O
,	O
48	O
,	O
49	O
],	O
to	O
produce	O
an	O
F1	O
.	O

F1	O
mice	B-OG
of	O
selected	O
genotypes	O
,	O
i	O
.	O
e	O
.	O
Rad54	B-GP
+/-/	O
Ptc1	B-GP
+/-	O
x	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/+	O
and	O
Rad54	B-GP
+/-/	O
Ptc1	B-GP
+/+	O
x	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-	O
were	O
crossed	O
to	O
produce	O
an	O
F2	O
population	O
.	O

Finally	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/+/	O
and	O
Rad54	B-GP
+/-/	O
Parp	B-GP
-	I-GP
1	I-GP
+/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
were	O
intercrossed	O
.	O

Genotyping	O
of	O
mice	B-OG
was	O
performed	O
as	O
described	O
[	O
21	O
,	O
49	O
].	O

Animal	O
treatment	O
and	O
irradiation	O

Mice	B-OG
were	O
housed	O
under	O
conventional	O
conditions	O
with	O
food	O
and	O
water	O
available	O
ad	O
libitum	O
and	O
a	O
12	O
-	O
h	O
light	O
cycle	O
.	O

For	O
long	O
-	O
term	O
study	O
,	O
mice	B-OG
were	O
irradiated	O
at	O
postnatal	O
day	O
1	O
(	O
P1	O
)	O
with	O
1	O
Gy	O
of	O
X	O
rays	O
.	O

Irradiation	O
was	O
performed	O
using	O
a	O
Gilardoni	O
CHF	O
320	O
G	O
X	O
-	O
ray	O
generator	O
(	O
Gilardoni	O
S	O
.	O
p	O
.	O
A	O
.,	O
Mandello	O
del	O
Lario	O
,	O
Italy	O
)	O
operated	O
at	O
250	O
kVp	O
,	O
5mA	O
,	O
Half	O
-	O
Value	O
Layer	O
=	O
1	O
.	O
6	O
mm	O
Cu	O
(	O
additional	O
filtration	O
of	O
2	O
.	O
0	O
mm	O
Al	O
and	O
0	O
.	O
5	O
mm	O
Cu	O
)	O
[	O
50	O
].	O

The	O
size	O
of	O
the	O
experimental	O
groups	O
was	O
chosen	O
to	O
ensure	O
statistical	O
relevance	O
.	O

Randomized	O
methods	O
were	O
applied	O
and	O
experiments	O
were	O
performed	O
blinded	O
.	O

All	O
experiments	O
were	O
conducted	O
according	O
to	O
the	O
directive	O
2010	O
/	O
63	O
/	O
EU	O
of	O
the	O
European	O
Parlament	O
.	O

Animal	O
studies	O
were	O
approved	O
and	O
permission	O
was	O
issued	O
by	O
“	O
Ministero	O
della	O
Salute	O
”	O
(	O
Approval	O
number	O
is	O
986	O
/	O
2015	O
-	O
PR	O
).	O

Histological	O
analysis	O
and	O
tumor	B-DS
quantification	O

Mice	B-OG
were	O
observed	O
daily	O
for	O
their	O
lifespan	O
.	O

Upon	O
decline	O
of	O
health	O
(	O
i	O
.	O
e	O
.,	O
severe	O
weight	O
loss	O
,	O
paralysis	O
,	O
ruffling	O
of	O
fur	O
,	O
or	O
inactivity	O
),	O
they	O
were	O
killed	O
and	O
autopsied	O
.	O

Normally	O
appearing	O
and	O
tumor	B-DS
bearing	O
brains	O
were	O
fixed	O
in	O
10	O
%	O
buffered	O
formalin	O
or	O
snap	O
frozen	O
in	O
liquid	O
nitrogen	O
.	O

Autopsied	O
mice	B-OG
were	O
also	O
checked	O
for	O
the	O
presence	O
of	O
any	O
other	O
tumor	B-DS
,	O
and	O
all	O
tumor	B-DS
masses	O
were	O
collected	O
and	O
processed	O
for	O
histological	O
analysis	O
using	O
standard	O
methods	O
.	O

MB	B-DS
incidence	O
was	O
expressed	O
as	O
the	O
percentage	O
of	O
mice	B-OG
with	O
tumors	B-DS
.	O

Tissue	O
collection	O

Brains	O
from	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
were	O
collected	O
at	O
P1	O
and	O
P7	O
.	O

Samples	O
were	O
fixed	O
in	O
10	O
%	O
buffered	O
formalin	O
.	O

For	O
mRNA	O
profiling	O
and	O
western	O
blot	O
analysis	O
P1	O
cerebella	O
were	O
snap	O
frozen	O
in	O
liquid	O
nitrogen	O
and	O
stored	O
at	O
-	O
80	O
°	O
C	O
.	O

Microsatellite	O
analysis	O
at	O
the	O
Ptc1	B-GP
locus	O
in	O
MB	B-DS

DNA	O
from	O
MBs	O
and	O
normal	O
tissue	O
was	O
extracted	O
using	O
Wizard	O
SV	O
Genomic	O
DNA	O
Purification	O
System	O
(	O
Promega	O
Corporation	O
,	O
Madison	O
,	O
WI	O
).	O

Polymerase	O
chain	O
reaction	O
amplifications	O
were	O
performed	O
as	O
described	O
previously	O
.	O

About	O
10	O
-	O
14	O
microsatellites	O
spanning	O
the	O
length	O
of	O
chromosome	O
(	O
chr	O
)	O
13	O
were	O
used	O
to	O
examine	O
tumor	B-DS
DNA	O
in	O
comparison	O
with	O
the	O
corresponding	O
genomic	O
DNA	O
[	O
51	O
].	O

Morphometric	O
analysis	O

Cerebella	O
external	O
granule	O
layer	O
(	O
EGL	O
)	O
and	O
internal	O
granule	O
layer	O
(	O
IGL	O
)	O
total	O
cross	O
sectional	O
areas	O
were	O
measured	O
in	O
at	O
least	O
3	O
samples	O
.	O

The	O
imaging	O
software	O
NIS	O
-	O
Elements	O
BR	O
4	O
.	O
00	O
.	O
05	O
(	O
Nikon	O
,	O
Instruments	O
Europe	O
B	O
.	O
V	O
.,	O
Italy	O
)	O
was	O
used	O
for	O
morphometric	O
analyses	O
.	O

Immunohistochemical	O
analysis	O

Cerebella	O
and	O
other	O
tissues	O
paraffin	O
sections	O
were	O
used	O
for	O
immunohistochemical	O
analysis	O
as	O
described	O
previously	O
[	O
50	O
].	O

Antibodies	O
used	O
were	O
Ki	B-GP
-	I-GP
67	I-GP
(	O
ab15580	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
),	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
(	O
9664	O
,	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
)	O
and	O
γ	O
-	O
H2AX	B-GP
(#	O
2577	O
,	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
NeuN	B-GP
(	O
MAB377	O
,	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
).	O

Ki	B-GP
-	I-GP
67	I-GP
quantification	O
:	O
Three	O
to	O
7	O
sections	O
from	O
EGL	O
of	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
were	O
immunostained	O
for	O
Ki67	B-GP
.	O

Images	O
were	O
captured	O
by	O
HistoFAXS	O
software	O
(	O
TissueGnostics	O
GmbH	O
,	O
Vienna	O
,	O
Austria	O
)	O
at	O
20x	O
magnification	O
.	O

Specific	O
regions	O
of	O
interest	O
(	O
EGL	O
)	O
were	O
analyzed	O
with	O
HistoQuest	O
software	O
(	O
TissueGnostics	O
)	O
for	O
automatic	O
color	O
separation	O
and	O
quantification	O
.	O

Expression	O
levels	O
were	O
evaluated	O
as	O
stained	O
area	O
per	O
μm2	O
.	O

γ	O
-	O
H2AX	B-GP
and	O
cleaved	O
-	O
caspase	B-GP
-	I-GP
3	I-GP
quantification	O
:	O
Three	O
to	O
5	O
sections	O
from	O
EGL	O
of	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
were	O
immunostained	O
for	O
γ	O
-	O
H2AX	B-GP
or	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
.	O
expression	O
levels	O
were	O
evaluated	O
counting	O
stained	O
positive	O
cells	O
/	O
EGL	O
area	O
(	O
mm2	O
).	O

NeuN	B-GP
quantification	O
:	O
Three	O
to	O
5	O
cerebellum	O
sections	O
of	O
Ptc1	B-GP
+/-,	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-,	O
Rad54	B-GP
-/-/	O
Ptc1	B-GP
+/-	O
and	O
Rad54	B-GP
-/-/	O
Parp	B-GP
-	I-GP
1	I-GP
-/-/	O
Ptc1	B-GP
+/-	O
mice	B-OG
were	O
immunostained	O
for	O
NeuN	B-GP
.	O

Expression	O
levels	O
of	O
NeuN	B-GP
were	O
evaluated	O
as	O
the	O
percentage	O
of	O
stained	O
positive	O
cells	O
in	O
a	O
fixed	O
area	O
(	O
10000	O
μm2	O
)	O
of	O
folia	O
VIII	O
for	O
each	O
cerebellum	O
.	O

Preparation	O
of	O
mouse	B-OG
embryonic	O
fibroblast	O
(	O
MEFs	O
)	O

MEFs	O
(	O
two	O
independent	O
embryos	O
per	O
genotype	O
)	O
were	O
generated	O
from	O
embryos	O
at	O
gestational	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
according	O
to	O
standard	O
protocols	O
[	O
52	O
].	O

Briefly	O
,	O
the	O
whole	O
embryo	O
was	O
disaggregated	O
using	O
a	O
mechanical	O
disaggregator	O
system	O
(	O
Medimax	O
,	O
CTSV	O
,	O
Bruino	O
,	O
TO	O
,	O
Italy	O
)	O
and	O
grown	O
in	O
DMEM	O
with	O
15	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
),	O
100	O
units	O
/	O
ml	O
penicillin	O
,	O
100	O
mg	O
/	O
ml	O
streptomycin	O
,	O
and	O
2mM	O
L	O
-	O
glutammine	O
,	O
in	O
a	O
humidified	O
incubator	O
with	O
5	O
%	O
CO2	O
.	O

All	O
experiments	O
were	O
performed	O
with	O
cells	O
that	O
had	O
been	O
subjected	O
to	O
2	O
passages	O
.	O

Sulforhodamine	O
B	O
(	O
SRB	O
)	O
assay	O

For	O
the	O
growth	O
curve	O
SRB	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
[	O
53	O
].	O

The	O
plate	O
was	O
analysed	O
at	O
510	O
nm	O
optical	O
density	O
in	O
the	O
VICTOR	O
X3	O
Multilabel	O
Plate	O
Reader	O
(	O
PerkinElmer	O
,	O
Waltham	O
,	O
MA	O
).	O

Doubling	O
time	O
(	O
Dt	O
)	O
was	O
calculated	O
with	O
the	O
formula	O
:	O
Dt	O
=	O
t	O
log2	O
/	O
(	O
log	O
n1	O
–	O
log	O
n0	O
),	O
where	O
n0	O
is	O
the	O
number	O
of	O
cell	O
at	O
time	O
t0	O
,	O
n1	O
is	O
the	O
number	O
of	O
cells	O
at	O
time	O
t1	O
and	O
t	O
is	O
the	O
time	O
in	O
exponential	O
growth	O
phase	O
required	O
by	O
cells	O
to	O
increase	O
their	O
number	O
from	O
n0	O
to	O
n1	O
(	O
t	O
=	O
t1	O
–	O
t0	O
).	O

SA	O
-	O
β	B-GP
-	I-GP
Gal	I-GP
staining	O

Cells	O
were	O
cultured	O
for	O
24	O
h	O
,	O
and	O
stained	O
using	O
the	O
Senescence	O
β	B-GP
-	I-GP
Galactosidase	I-GP
Staining	O
Kit	O
(	O
Cell	O
Signalling	O
Technology	O
).	O

SA	O
-	O
β	B-GP
-	I-GP
Gal	I-GP
staining	O
of	O
MEFs	O
was	O
performed	O
following	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
Percentage	O
of	O
cells	O
expressing	O
SA	O
-	O
β	B-GP
-	I-GP
Gal	I-GP
was	O
quantified	O
by	O
inspecting	O
at	O
least	O
1000	O
cells	O
in	O
at	O
least	O
two	O
different	O
cell	O
lines	O
for	O
each	O
genotype	O
.	O

Immunoblotting	O

Appropriate	O
amounts	O
of	O
proteins	O
(	O
30	O
μg	O
or	O
60	O
μg	O
),	O
extracted	O
from	O
a	O
pool	O
of	O
3	O
P1	O
-	O
cerebella	O
and	O
MEFs	O
were	O
loaded	O
and	O
separated	O
by	O
SDS	O
-	O
PAGE	O
.	O

Proteins	O
were	O
electro	O
transferred	O
to	O
PVDF	O
or	O
nitrocellulose	O
membranes	O
(	O
Trans	O
-	O
Blot	O
Turbo	O
Transfer	O
Pack	O
,	O
BIO	O
-	O
RAD	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
)	O
at	O
the	O
Trans	O
-	O
Blot	O
Turbo	O
Transfer	O
System	O
(	O
BIO	O
-	O
RAD	O
Laboratories	O
).	O

After	O
blocking	O
,	O
membranes	O
were	O
incubated	O
over	O
night	O
at	O
+	O
4	O
°	O
C	O
with	O
primary	O
antibodies	O
against	O
DNA	B-GP
-	I-GP
PKcs	I-GP
and	O
p53	B-GP
(	O
ab70250	O
and	O
ab31333	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
),	O
ATM	B-GP
,	O
p21	B-GP
(	O
sc	O
-	O
23921	O
and	O
sc	O
-	O
471	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
),	O
anti	O
-	O
phospho	O
-	O
p53	B-GP
(	O
Ser18	O
)	O
(	O
9284	O
,	O
Cell	O
Signaling	O
Technology	O
,	O
Inc	O
.,	O
Danvers	O
,	O
MA	O
),	O
β	B-GP
-	I-GP
actin	I-GP
and	O
HSP70	B-GP
(	O
A5316	O
and	O
H5147	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
).	O

Membranes	O
were	O
probed	O
for	O
1h	O
at	O
RT	O
with	O
appropriated	O
HRP	O
-	O
conjugated	O
secondary	O
antibodies	O
(	O
Santa	O
Cruz	O
Biotechnology	O
).	O

Immunoreactive	O
bands	O
were	O
visualized	O
using	O
Amersham	O
ECL	O
Prime	O
WB	O
detection	O
reagent	O
(	O
GE	O
Healthcare	O
Europe	O
,	O
Milan	O
,	O
Italy	O
).	O

Images	O
were	O
acquired	O
using	O
a	O
Image	O
6	O
quant	O
LAS	O
500	O
(	O
GE	O
Healthcare	O
Europe	O
),	O
and	O
densitometric	O
analysis	O
was	O
performed	O
using	O
ImageJ	O
software	O
.	O

mRNA	O
extraction	O
and	O
reverse	O
transcription	O

Three	O
to	O
7	O
cerebella	O
were	O
pooled	O
for	O
each	O
genotype	O
.	O

mRNA	O
was	O
extracted	O
with	O
RNeasy	O
Microarray	O
Tissue	O
kit	O
(	O
Qiagen	O
,	O
Germany	O
)	O
in	O
accordance	O
with	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Reverse	O
transcription	O
was	O
accomplished	O
with	O
the	O
RT2	O
First	O
Strand	O
kit	O
(	O
Qiagen	O
,	O
Germany	O
)	O
as	O
suggested	O
by	O
manufacturer	O
.	O

RT2	O
Profiler	O
PCR	O
Array	O

RT2	O
RNA	O
QC	O
PCR	O
Array	O
(	O
SaBiosciences	O
,	O
Qiagen	O
,	O
Germany	O
)	O
was	O
used	O
to	O
test	O
for	O
RNA	O
quality	O
and	O
inhibitors	O
of	O
RT	O
-	O
PCR	O
analysis	O
.	O

For	O
quantitative	O
comparison	O
of	O
mRNA	O
levels	O
,	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
using	O
RT2	O
Profiler	O
PCR	O
Arrays	O
Mouse	B-OG
DNA	O
Damage	O
(	O
SaBiosciences	O
,	O
Qiagen	O
).	O

For	O
each	O
genotype	O
,	O
two	O
assays	O
were	O
carried	O
out	O
.	O

Gene	O
expression	O
was	O
related	O
to	O
the	O
mean	O
expression	O
of	O
all	O
five	O
housekeeping	O
genes	O
included	O
in	O
the	O
array	O
.	O

Only	O
Ct	O
values	O
<	O
35	O
were	O
included	O
in	O
the	O
calculations	O
.	O

Data	O
presented	O
are	O
averages	O
of	O
two	O
independent	O
experiments	O
.	O

Prkdc	B-GP
and	O
Atm	B-GP
genes	O
were	O
further	O
validated	O
by	O
SYBR	O
Green	O
real	O
-	O
time	O
PCR	O
(	O
SaBiosciences	O
,	O
Qiagen	O
).	O

The	O
PCR	O
primers	O
for	O
mouse	B-OG
Atm	B-GP
(	O
PPM03454C	O
-	O
200	O
RT2	O
qPCR	O
Primer	O
Assay	O
)	O
and	O
Prkdc	B-GP
(	O
PPM03711E	O
-	O
200	O
RT2	O
qPCR	O
Primer	O
Assay	O
)	O
were	O
purchased	O
from	O
SABiosciences	O
,	O
Qiagen	O
and	O
real	O
-	O
time	O
PCR	O
were	O
performed	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Data	O
represent	O
the	O
average	O
of	O
three	O
independent	O
experiments	O
.	O

Bioinformatic	O
analysis	O

Hierarchical	O
clustering	O
analysis	O
was	O
performed	O
to	O
evaluate	O
similarities	O
among	O
the	O
three	O
genotypes	O
when	O
compared	O
to	O
Ptc1	B-GP
+/-	O
mice	B-OG
.	O

Euclidean	O
distance	O
matrices	O
were	O
performed	O
in	O
R	O
(	O
http	O
://	O
www	O
.	O
r	O
-	O
project	O
.	O
org	O
/)	O
using	O
the	O
fold	O
change	O
of	O
each	O
gene	O
.	O

Heat	O
map	O
visualization	O
generated	O
by	O
R	O
package	O
“	O
gplots	O
”	O
was	O
used	O
to	O
show	O
RT2	O
Profiler	O
PCR	O
Arrays	O
Mouse	B-OG
DNA	O
Damage	O
.	O

To	O
estimate	O
genotype	O
-	O
dependent	O
pathway	O
perturbations	O
,	O
the	O
Signaling	O
Protein	O
Impact	O
Analysis	O
(	O
SPIA	O
)	O
[	O
54	O
]	O
algorithm	O
based	O
on	O
KEGG	O
(	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
)	O
database	O
was	O
applied	O
using	O
the	O
online	O
tool	O
Graphite	O
(	O
http	O
://	O
graphiteweb	O
.	O
bio	O
.	O
unipd	O
.	O
it	O
/	O
index	O
.	O
html	O
).	O

Significantly	O
perturbed	O
genes	O
obtained	O
from	O
SPIA	O
were	O
analyzed	O
by	O
the	O
Cytoscape	O
tool	O
[	O
55	O
]	O
to	O
evaluate	O
the	O
most	O
perturbed	O
pathways	O
.	O

Statistical	O
analysis	O

Appropriate	O
statistical	O
tests	O
were	O
used	O
.	O

Analyses	O
were	O
performed	O
using	O
GraphPad	O
Prism	O
version	O
4	O
.	O
02	O
for	O
Windows	O
(	O
GraphPad	O
Software	O
,	O
San	O
Diego	O
,	O
CA	O
).	O

Statistical	O
comparisons	O
were	O
made	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curves	O
were	O
compared	O
and	O
log	O
rank	O
test	O
P	O
values	O
were	O
calculated	O
.	O
P	O
values	O
≤	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

SUPPLEMENTARY	O
MATERIALS	O
FIGURE	O
AND	O
TABLE	O

CONFLICTS	O
OF	O
INTEREST	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
conflict	O
of	O
interest	O
.	O

Editorial	O
Note	O

This	O
papers	O
has	O
been	O
accepteds	O
based	O
in	O
part	O
on	O
peer	O
-	O
review	O
conducted	O
by	O
another	O
journal	O
and	O
the	O
authors	O
’	O
response	O
and	O
revisions	O
as	O
well	O
as	O
expedited	O
peer	O
-	O
review	O
in	O
Oncotarget	O
.	O

